New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era

New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era

Introduction: EGFR-mutated non-small cell lung cancer (EGFRmut NSCLC) represents a heterogeneous group of tumors with varying clinical outcomes. Resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), is inevitable, with emerging evidence suggesting that concurrent g...

Full description

Saved in:
Bibliographic Details
Main Authors: Jaime Rubio-Perez, Roberto Hernandez, Carlota Santolaya, Maria Cruz Martin-Soberon, Sandra Zazo, Nerea Carvajal, Federico Rojo
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Cancer Treatment and Research Communications
Subjects:
EGFR-mutated NSCLC
TP53 mutations
TKI resistance
NGS
Targeted therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294225000814
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2468294225000814

Similar Items